Abraxis BioScience's (ABII) ABRAXANE Approved for Advanced Breast Cancer Patient Treatment in Quebec

FREE Breaking News Alerts from StreetInsider.com!

More News related to ABII

Abraxis Bioscience (ABII) Shareholders Approve Merger with Celgene (CELG)
Celgene Corp. (CELG) Gets Verbal Confirmation of Early HSR Act Termination in Abraxis (ABII) Acquisition
Abraxis BioScience's (ABII) Breast Cancer Treatment ABRAXANE OK'd to Market in Japan
Top 10 News Items for 6/28-7/2: Nonfarm Payrolls Beat, Unemployment Rate Comes in at 9.5%; Tesla's IPO En Fuego; House Passes FinReg Bill
Notable 52-Week High's and Low's of the Day 06/30: STST, ABII High; YHOO, MON, SUPG, RIMM Low

More News related to FDA

June 29, 2009 8:45 AM EDT

Abraxis BioScience, Inc. (NASDAQ: ABII) announced the listing of ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg in Quebec for the treatment of metastatic breast cancer with a recommendation from the Quebec Conseil du Medicament and approval from the Quebec Ministry of Health. ABRAXANE is approved and commercially available in Canada for the treatment of metastatic breast cancer, including first-line disease. The listing of ABRAXANE in Quebec offers an important new treatment option to Quebec women with advanced breast cancer.

Sign up at EasyStockAlerts for free to see your stock news before it breaks to the rest of the public!